Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;108(4):1196-1199.
doi: 10.3324/haematol.2022.281856.

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Joshua F Zeidner  1 , Flora Mazerolle  2 , Jonathan Norton  3 , Antoine Regnault  2 , Fjoralba Kristo  3 , Heather Romero  3 , Robert J Fram  3 , Douglas V Faller  3 , Mehul Dalal  3 , Lionel Ades  4 , Mikkael A Sekeres  5
Affiliations

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Joshua F Zeidner et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Partitioned survival plot of the transfusion dependence, time without transfusion reliance and relapse states in high-risk myelodysplatic syndromes subpopulation from the P-2001 study who had a patient-reported outcome assessment at baseline and at least one post-baseline assessment (N=63). TD: transfusion dependence; TWiTR: time without transfusion reliance; REL: relapse.
See this image and copyright information in PMC

References

    1. Zeidner JF, Mazerolle F, Bell JA, et al. . Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine in higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast acute myeloid leukemia: exploratory analysis of patient-reported outcomes. Blood. 2020;136(Suppl 1):S39-40.
    1. Oliva EN, Platzbecker U, Fenaux P, et al. . Targeting health-related quality of life in patients with myelodysplastic syndromes – current knowledge and lessons to be learned. Blood Rev. 2021;50:100851. - PubMed
    1. Bell JA, Galaznik A, Blazer M, et al. . Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. Leuk Lymphoma. 2019;60(1):49-59. - PubMed
    1. Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned? Crit Rev Oncol Hematol. 2015;96(3):542-554. - PubMed
    1. Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat. 1995;49(2):161-169.

Publication types